These analyses revealed that the presence of combined MetS, along with IPI scores, Ki-67 expression levels, and the application of rituximab, could serve as independent predictors of prognosis in DLBCL (Table 5). The gene discussed is MKI67; the disease is diffuse large B-cell lymphoma.